SESN Jan 2024 1.000 call
| Previous close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.1000 |
| Ask | 0.1500 |
| Strike | 1.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.1000 - 0.1400 |
| Contract range | N/A |
| Volume | |
| Open interest | 13.96k |
- Business Wire
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
CAMBRIDGE, Mass., January 26, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the "Investor Group"):
- Business Wire
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
HOUSTON, January 25, 2023--Bradley L. Radoff and Michael Torok (together with their affiliates, the "Investor Group" or "we"), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio"), today issued the following open letter to the Boards of Directors (collectively, the "Boards") of Sesen Bio and Carisma Therapeutics Inc. ("Carisma" and together with Sesen Bio, the "Companies"):
- Business Wire
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
CAMBRIDGE, Mass., January 19, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about
